QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:CCXI

ChemoCentryx - CCXI Stock Forecast, Price & News

$50.79
-0.10 (-0.20%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$50.56
$50.94
50-Day Range
$21.76
$50.89
52-Week Range
$13.11
$50.94
Volume
8.32 million shs
Average Volume
1.66 million shs
Market Capitalization
$3.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.25

ChemoCentryx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
28.5% Upside
$65.25 Price Target
Short Interest
Bearish
11.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.75
Upright™ Environmental Score
News Sentiment
0.03mentions of ChemoCentryx in the last 14 days
Based on 38 Articles This Week
Insider Trading
Selling Shares
$9.84 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.94) to ($0.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

408th out of 1,098 stocks

Pharmaceutical Preparations Industry

182nd out of 536 stocks

CCXI stock logo

About ChemoCentryx (NASDAQ:CCXI) Stock

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CCXI shares. StockNews.com cut shares of ChemoCentryx from a "hold" rating to a "sell" rating in a research report on Tuesday, August 2nd. Canaccord Genuity Group began coverage on shares of ChemoCentryx in a report on Thursday, August 4th. They issued a "buy" rating and a $81.00 price target on the stock. Canaccord Genuity Group cut shares of ChemoCentryx from a "buy" rating to a "hold" rating and set a $52.00 price target on the stock. in a report on Friday. SVB Leerink lowered shares of ChemoCentryx from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $64.00 to $52.00 in a research note on Friday. Finally, HC Wainwright lowered shares of ChemoCentryx from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $101.00 to $52.00 in a research note on Friday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $65.11.

ChemoCentryx Price Performance

ChemoCentryx stock traded down $0.24 during trading on Tuesday, reaching $50.65. The company had a trading volume of 200,205 shares, compared to its average volume of 2,944,299. The firm's 50-day simple moving average is $25.84 and its 200 day simple moving average is $24.58. ChemoCentryx has a 1-year low of $13.11 and a 1-year high of $50.90. The firm has a market capitalization of $3.61 billion, a PE ratio of -25.22 and a beta of 1.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.07 and a current ratio of 5.11.

Insider Activity at ChemoCentryx

In related news, CEO Thomas J. Schall sold 130,000 shares of ChemoCentryx stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $50.24, for a total value of $6,531,200.00. Following the sale, the chief executive officer now owns 2,393,352 shares of the company's stock, valued at approximately $120,242,004.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other ChemoCentryx news, CEO Thomas J. Schall sold 130,000 shares of the firm's stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.24, for a total value of $6,531,200.00. Following the transaction, the chief executive officer now directly owns 2,393,352 shares of the company's stock, valued at approximately $120,242,004.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Susan M. Kanaya sold 46,298 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.17, for a total value of $2,322,770.66. Following the completion of the sale, the chief financial officer now directly owns 91,317 shares of the company's stock, valued at approximately $4,581,373.89. The disclosure for this sale can be found here. In the last quarter, insiders have sold 197,725 shares of company stock valued at $9,835,159. 8.30% of the stock is owned by company insiders.

Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

CCXI Stock News Headlines

ChemoCentryx (NASDAQ:CCXI) Cut to Neutral at HC Wainwright
ChemoCentryx (CCXI) Scheduled to Post Earnings on Tuesday
ChemoCentryx Stock More Than Doubles On $4B Buyout
Amgen to Acquire ChemoCentryx in $3.7bn Deal
Amgen to buy ChemoCentryx for billions in cash
ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why
3 Analysts Have This to Say About ChemoCentryx
Amgen Acquires Drugmaker ChemoCentryx for $3.7 Billion
See More Headlines
Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

CCXI Company Calendar

Last Earnings
11/08/2021
Today
8/09/2022
Next Earnings (Confirmed)
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CCXI
CUSIP
16383L10
Employees
178
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$65.25
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+28.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-131,760,000.00
Net Margins
-514.64%
Pretax Margin
-514.64%

Debt

Sales & Book Value

Annual Sales
$32.22 million
Book Value
$4.09 per share

Miscellaneous

Free Float
65,284,000
Market Cap
$3.62 billion
Optionable
Optionable
Beta
1.67

Key Executives

  • Dr. Thomas J. Schall Ph.D. (Age 63)
    Founder, Pres, CEO & Chairman
    Comp: $1.21M
  • Ms. Susan M. Kanaya (Age 59)
    Exec. VP, Chief Financial & Admin. Officer, Sec. and Director
    Comp: $845.04k
  • Mr. Tausif Butt (Age 56)
    Exec. VP & COO
    Comp: $1.01M
  • Dr. Rita I. Jain M.D. (Age 59)
    Exec. VP, Chief Medical Officer & Exec. Employee Director
    Comp: $670.7k
  • Dr. Markus J. Cappel Ph.D. (Age 61)
    Chief Bus. Officer & Treasurer
    Comp: $643.58k
  • Ms. Yi Ching Yau (Age 46)
    Sr. VP of Fin. & Principal Accounting Officer
  • Mr. William S. Slattery
    VP of Investor Relations & Corp. Communications
  • Ms. Kari E. Leetch
    Sr. VP of HR
  • Dr. Sangita Ghosh Ph.D.
    Sr. VP of Technical Operations













CCXI Stock - Frequently Asked Questions

Should I buy or sell ChemoCentryx stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are currently 4 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CCXI shares.
View CCXI analyst ratings
or view top-rated stocks.

What is ChemoCentryx's stock price forecast for 2022?

8 brokerages have issued twelve-month target prices for ChemoCentryx's shares. Their CCXI share price forecasts range from $38.00 to $110.00. On average, they predict the company's share price to reach $65.25 in the next year. This suggests a possible upside of 28.8% from the stock's current price.
View analysts price targets for CCXI
or view top-rated stocks among Wall Street analysts.

How has ChemoCentryx's stock price performed in 2022?

ChemoCentryx's stock was trading at $36.41 at the beginning of 2022. Since then, CCXI shares have increased by 39.1% and is now trading at $50.65.
View the best growth stocks for 2022 here
.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our CCXI earnings forecast
.

How can I listen to ChemoCentryx's earnings call?

ChemoCentryx will be holding an earnings conference call on Tuesday, August 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) posted its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.13. The biopharmaceutical company had revenue of $17.74 million for the quarter, compared to the consensus estimate of $14.70 million. ChemoCentryx had a negative net margin of 514.64% and a negative trailing twelve-month return on equity of 47.24%. During the same quarter in the previous year, the company posted ($0.35) earnings per share.

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

21 employees have rated ChemoCentryx Chief Executive Officer Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among the company's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 44.0% of employees surveyed would recommend working at ChemoCentryx to a friend.

What other stocks do shareholders of ChemoCentryx own?

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by many different institutional and retail investors. Top institutional investors include Pictet Asset Management SA (3.33%), Integral Health Asset Management LLC (0.81%), Thornburg Investment Management Inc. (0.31%), Lisanti Capital Growth LLC (0.26%), Assenagon Asset Management S.A. (0.20%) and Swiss National Bank (0.19%). Insiders that own company stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends
.

How do I buy shares of ChemoCentryx?

Shares of CCXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $50.65.

How much money does ChemoCentryx make?

ChemoCentryx (NASDAQ:CCXI) has a market capitalization of $3.61 billion and generates $32.22 million in revenue each year. The biopharmaceutical company earns $-131,760,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does ChemoCentryx have?

ChemoCentryx employs 178 workers across the globe.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The official website for the company is www.chemocentryx.com. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at investor@chemocentryx.com, or via fax at 650-210-2910.

This page (NASDAQ:CCXI) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.